RCE is delighted to announce that it has been invited to join two new projects run by the EFPIA Oncology Platform (EOP). RCE will be joining the advisory board of experts and key opinion leaders of the EOP project, Making the policy case for novel endpoints in oncology, and will also be collaborating on EFPIA’s multi-stakeholder project, Sustainable Cancer Care Through Innovation.
Working in partnership with EOP members and other stakeholders as part of the EOP project on novel endpoints in oncology, RCE will be working to effectively communicate the value of adopting novel endpoints and real-world evidence in the drug development and approval processes, to create a faster and more responsive innovation pathway.
Extending overall survival is an important treatment goal for many therapies in oncology. In clinical trials, overall survival is widely considered as the endpoint that is most valued by patients, clinicians, regulators, and payers. However, mature data on overall survival are often not available at the time when reimbursement authorisation decisions for new therapies are being made. This is increasingly the case as new oncology medicines are often approved in earlier phases of development. This project will therefore look at the development of a framework that supports access to new treatments and addresses concerns on the clinical and economic benefits derived from immature trial data.
Furthermore, RCE will be collaborating on EFPIA’s multi-stakeholder project, ‘Sustainable Cancer Care Through Innovation’. The project aims to showcase real-world examples of high-quality care pathways and innovation, thus helping to improve sustainable patient access to high-quality cancer care as well as achieving the goals of Europe’s Beating Cancer Plan and the Mission on Cancer, by creating a series of recommendations on how to make cancer care more sustainable.
The project aims to answer the following points:
- What are the key challenges in terms of sustainability of cancer care?
- Why is innovation a key driver of improved sustainability?
- What are real-world examples demonstrating this?
- What are challenges hampering sustainable and innovation-friendly cancer care?
- How can we make cancer care more sustainable and innovation friendly?
RCE will therefore contribute and provide the perspective of the rare cancer community, using relevant case studies, to ensure that the final deliverable takes account of the unique challenges posed by rare cancers.